Endothelin Inhibition: Novel Therapy for Prostate Cancer
- 1 December 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 170 (6S) , S65-S68
Abstract
Androgen refractory prostate cancer continues to evade effective treatment. The potent vasoconstrictor endothelin-1 is produced by prostate cancer and appears to have a role in prostate cancer progression and morbidity. Background on the endothelin axis (endothelin-1 and endothelin receptors ET(A) and ET(B)), preclinical studies of its role in prostate cancer, results of phases I and II clinical trials, and future directions are reviewed. A review was conducted of the published data on the endothelin axis in prostate cancer. Based on preclinical and clinical trial data, the endothelin axis is emerging as potentially important in the biology of prostate cancer progression and morbidity. Drugs targeting the endothelin axis, such as the potent ET(A) receptor antagonist atrasentan (ABT-627), have been studied in large clinical trials and appear to have an impact on disease progression and morbidity. The role of the endothelin axis in prostate cancer deserves further investigation in the laboratory and clinic. This new strategy for intervention is promising.Keywords
This publication has 15 references indexed in Scilit:
- Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and PharmacokineticsJournal of Clinical Oncology, 2002
- EXPRESSION OF ENDOTHELIN RECEPTOR A ASSOCIATED WITH PROSTATE CANCER PROGRESSIONJournal of Urology, 2001
- Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostateNature Medicine, 1995
- Interleukin-6: A candidate mediator of human prostate cancer morbidityUrology, 1995
- Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorptionEndocrinology, 1992
- Endothelin inhibits osteoclastic bone resorption by a direct effect on cell motility: implications for the vascular control of bone resorption.Endocrinology, 1992
- Massive amounts of immunoreactive endothelin in human seminal fluid.The Journal of Clinical Endocrinology & Metabolism, 1992
- Massive amounts of immunoreactive endothelin in human seminal fluidThe Journal of Clinical Endocrinology & Metabolism, 1992
- A novel potent vasoconstrictor peptide produced by vascular endothelial cellsNature, 1988
- CpG-rich islands and the function of DNA methylationNature, 1986